search
Back to results

Enhancing the Effects of Adolescent Alcohol Treatment With Acetyl-L-Carnitine

Primary Purpose

Alcohol Use Disorder

Status
Not yet recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Acetyl-l-carnitine
Placebo
Sponsored by
Brown University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Use Disorder

Eligibility Criteria

14 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be 14 to 20 years old, inclusive
  2. Self-report consuming alcohol ≥ 2 days/week on average in the past 28 days
  3. Meets the DSM-5 criteria for alcohol use disorder (AUD)
  4. Be interested in reducing alcohol use
  5. Report at least mild depressive symptoms, as indicated by a score ≥ 14 on the Beck Depression Inventory II.
  6. Be able to verbalize an understanding of the consent/assent form, able to provide written informed consent/assent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
  7. Have parent permission, if younger than 18 years
  8. Be able to take oral medication and be willing to adhere to the medication regimen
  9. Complete all assessments required at screening and baseline.
  10. Provide contact information of someone, such as a parent or other family member, who may be able to contact the subject in case of a missed appointment or follow-up assessment.
  11. Agree to the schedule of visits, verbally acknowledge ability to attend each scheduled visit, participate in phone visits and report no scheduled events or a job that may substantially interfere with study participation.
  12. Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months.
  13. Agree (if the subject's sex is female and of childbearing potential) to use at least one reliable method of birth control, unless subject is surgically sterile, partner is surgically sterile, or subject is postmenopausal. Examples of reliable methods include (but may not be limited to):

    1. oral contraceptives
    2. contraceptive sponge
    3. contraceptive skin patch
    4. double barrier diaphragm (diaphragm/spermicidal or condom/spermicidal)
    5. intrauterine contraceptive system
    6. levonorgestrel implant
    7. medroxyprogesterone acetate contraceptive injection
    8. complete abstinence from sexual intercourse
    9. hormonal vaginal contraceptive ring

Exclusion Criteria:

  1. Be currently receiving alcohol use disorder treatment
  2. Have significant alcohol withdrawal symptoms (score > 10) on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-AR)
  3. Have a coexisting moderate to severe substance use disorder other than cannabis and nicotine, as defined by DSM-5 criteria
  4. Have a urine toxicology screen positive performed during screening or baseline for any of the following substances:

    1. benzodiazepines
    2. cocaine
    3. opiates
    4. amphetamines
    5. buprenorphine
    6. methadone
    7. barbiturates
    8. oxycodone
    9. 3, 4-methylenedioxy-methamphetamine (MDMA, also known as ecstasy)
    10. methamphetamines
  5. Have been treated with a pharmacotherapy for alcohol use disorder or a carbonic anhydrase inhibitor within 30 days prior to randomization
  6. Compelled to alcohol treatment by the juvenile justice system or has probation or parole requirements that might interfere with study participation
  7. Have a history of liver disease or have clinically significant abnormal laboratory values, including elevation of liver enzymes (AST, ALT) 5-fold above the upper limit of normal (ULN), or bilirubin greater than 2 times the upper limit of normal.
  8. History of renal impairment or renal stones, heart problems or defects, abnormal blood pressure, progressive neurodegenerative disorder, or clinically significant neurological disorders
  9. Clinically significant physical abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis
  10. Pregnancy, nursing, or refusal to use reliable birth control, if female of childbearing potential
  11. Stable dose of any prescribed psychotropic medication (i.e., no dose changes in the 2 months prior to randomization)
  12. Current or lifetime diagnosis of psychotic disorders or current bipolar disorder
  13. Current suicidality risk
  14. Known sensitivity to acetyl-l-carnitine
  15. Be a subject who in the opinion of the investigator could not be safely withdrawn from alcohol without medical detoxification
  16. Have a serious or unstable medical illness or any potentially life-threatening or progressive medical condition other than addiction that may compromise subject safety or study conduct
  17. Have abnormal calculated creatinine clearance defined as < 80 mL/min
  18. Have data suggesting cirrhosis of the liver (albumin < 3.2 g/dL, or ascites by physical exam)

Sites / Locations

  • Brown University Center for Alcohol and Addiction Studies

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Acetyl-L-Carnitine

Placebo

Arm Description

Acetyl-L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 3 g daily for 6 weeks

Daily for 6 weeks

Outcomes

Primary Outcome Measures

Alcohol Craving (derived from the Alcohol Urge Questionnaire; 0 to 20; higher scores = greater urge to drink)
Strength of self-reported alcohol craving

Secondary Outcome Measures

Full Information

First Posted
April 21, 2022
Last Updated
March 21, 2023
Sponsor
Brown University
Collaborators
Rhode Island Hospital, Colorado State University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT05355311
Brief Title
Enhancing the Effects of Adolescent Alcohol Treatment With Acetyl-L-Carnitine
Official Title
Acetyl-L-carnitine Supplementation for Co-occurring Depression and Alcohol Use Disorder in Adolescents: A Randomized Placebo-Controlled Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 2023 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Brown University
Collaborators
Rhode Island Hospital, Colorado State University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to evaluate the effects of acetyl-L-carnitine (ALCAR), 3 g daily, and matched placebo on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 4 weeks of daily dosing among participants ages 14-20 with alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™) and who report at least mild depressive symptoms on the Beck Depression Inventory-II. Secondary objectives include evaluation of ALCAR (3g/day) and matched placebo on alcohol craving and use, subjective effects of alcohol consumption, mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
This study is a 2-arm, double-blind, randomized, placebo-controlled, parallel group, single-site study designed to assess the effects of acetyl-L-carnitine supplementation as compared with placebo on responses to in vivo alcohol cue exposure in the human laboratory setting.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double-blind
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acetyl-L-Carnitine
Arm Type
Experimental
Arm Description
Acetyl-L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 3 g daily for 6 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Daily for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Acetyl-l-carnitine
Other Intervention Name(s)
L-carnitine
Intervention Description
Acetyl-L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar Pill
Intervention Description
Matching placebo (sugar pill)
Primary Outcome Measure Information:
Title
Alcohol Craving (derived from the Alcohol Urge Questionnaire; 0 to 20; higher scores = greater urge to drink)
Description
Strength of self-reported alcohol craving
Time Frame
Week 5

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be 14 to 20 years old, inclusive Self-report consuming alcohol ≥ 2 days/week on average in the past 28 days Meets the DSM-5 criteria for alcohol use disorder (AUD) Be interested in reducing alcohol use Report at least mild depressive symptoms, as indicated by a score ≥ 14 on the Beck Depression Inventory II. Be able to verbalize an understanding of the consent/assent form, able to provide written informed consent/assent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol. Have parent permission, if younger than 18 years Be able to take oral medication and be willing to adhere to the medication regimen Complete all assessments required at screening and baseline. Provide contact information of someone, such as a parent or other family member, who may be able to contact the subject in case of a missed appointment or follow-up assessment. Agree to the schedule of visits, verbally acknowledge ability to attend each scheduled visit, participate in phone visits and report no scheduled events or a job that may substantially interfere with study participation. Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months. Agree (if the subject's sex is female and of childbearing potential) to use at least one reliable method of birth control, unless subject is surgically sterile, partner is surgically sterile, or subject is postmenopausal. Examples of reliable methods include (but may not be limited to): oral contraceptives contraceptive sponge contraceptive skin patch double barrier diaphragm (diaphragm/spermicidal or condom/spermicidal) intrauterine contraceptive system levonorgestrel implant medroxyprogesterone acetate contraceptive injection complete abstinence from sexual intercourse hormonal vaginal contraceptive ring Exclusion Criteria: Be currently receiving alcohol use disorder treatment Have significant alcohol withdrawal symptoms (score > 10) on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-AR) Have a coexisting moderate to severe substance use disorder other than cannabis and nicotine, as defined by DSM-5 criteria Have a urine toxicology screen positive performed during screening or baseline for any of the following substances: benzodiazepines cocaine opiates amphetamines buprenorphine methadone barbiturates oxycodone 3, 4-methylenedioxy-methamphetamine (MDMA, also known as ecstasy) methamphetamines Have been treated with a pharmacotherapy for alcohol use disorder or a carbonic anhydrase inhibitor within 30 days prior to randomization Compelled to alcohol treatment by the juvenile justice system or has probation or parole requirements that might interfere with study participation Have a history of liver disease or have clinically significant abnormal laboratory values, including elevation of liver enzymes (AST, ALT) 5-fold above the upper limit of normal (ULN), or bilirubin greater than 2 times the upper limit of normal. History of renal impairment or renal stones, heart problems or defects, abnormal blood pressure, progressive neurodegenerative disorder, or clinically significant neurological disorders Clinically significant physical abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis Pregnancy, nursing, or refusal to use reliable birth control, if female of childbearing potential Stable dose of any prescribed psychotropic medication (i.e., no dose changes in the 2 months prior to randomization) Current or lifetime diagnosis of psychotic disorders or current bipolar disorder Current suicidality risk Known sensitivity to acetyl-l-carnitine Be a subject who in the opinion of the investigator could not be safely withdrawn from alcohol without medical detoxification Have a serious or unstable medical illness or any potentially life-threatening or progressive medical condition other than addiction that may compromise subject safety or study conduct Have abnormal calculated creatinine clearance defined as < 80 mL/min Have data suggesting cirrhosis of the liver (albumin < 3.2 g/dL, or ascites by physical exam)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Miranda, PhD
Phone
401-863-6658
Email
Robert_Miranda_Jr@brown.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Brianna Parlette, ScM
Phone
401-863-6687
Email
Brianna_Parlette@brown.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Miranda, PhD
Organizational Affiliation
Brown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brown University Center for Alcohol and Addiction Studies
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
With participant consent, data will be uploaded into appropriate NIH repository as required.
IPD Sharing Time Frame
Within 12 months of publication
IPD Sharing Access Criteria
Any investigator who requests access in writing will be provided with the requested information.

Learn more about this trial

Enhancing the Effects of Adolescent Alcohol Treatment With Acetyl-L-Carnitine

We'll reach out to this number within 24 hrs